Home › Funds › Paradigm Biocapital Advisors LP › ALNY
Paradigm Biocapital Advisors LP position in ALNY
ALNYLAM PHARMACEUTICALS INC · Health Care
Paradigm Biocapital Advisors LP reported holding 480,000 shares of ALNY (ALNYLAM PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$144.5M, representing 2.71% of its reported portfolio and ranking #12 among its reported holdings. Paradigm Biocapital Advisors LP first reported this position in Q2 2026.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Paradigm Biocapital Advisors LP's ALNY position evolved
Paradigm Biocapital Advisors LP first disclosed a stake in ALNY in Q2 2026 at 480,000 shares (US$144.5M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2026 | 480.00K | $144.49M | New |
About ALNY and 13F data
ALNY (ALNYLAM PHARMACEUTICALS INC) is a Health Care company. 36 other funds we track also report a position in ALNY — the largest reported positions include T. Rowe Price Investment Management, Inc. (US$1.70B), Baillie Gifford & Co (US$734.5M), Orbis Allan Gray Ltd (US$598.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding ALNY
- T. Rowe Price Investment Management, Inc. 5.64M sh · $1.70B · Q2 2026
- Baillie Gifford & Co 2.44M sh · $734.48M · Q2 2026
- Orbis Allan Gray Ltd 1.99M sh · $598.27M · Q2 2026
- Two Sigma Investments 1.88M sh · $564.71M · Q2 2026
- AMERICAN CENTURY COMPANIES INC 1.85M sh · $558.10M · Q2 2026
- TWO SIGMA ADVISERS, LP 1.13M sh · $450.36M · Q4 2025
- Deep Track Capital, LP 825.00K sh · $248.35M · Q2 2026
- Qube Research & Technologies Ltd 798.72K sh · $240.44M · Q2 2026
- LOS ANGELES CAPITAL MANAGEMENT LLC 729.63K sh · $219.64M · Q2 2026
- LOOMIS SAYLES & CO L P 580.19K sh · $174.65M · Q2 2026
More on Paradigm Biocapital Advisors LP
FAQ
How long has Paradigm Biocapital Advisors LP held ALNY?
Paradigm Biocapital Advisors LP has disclosed ALNY holdings in 1 of the last 1 reported quarters, going back to Q2 2026.
What is Paradigm Biocapital Advisors LP's current position in ALNY?
As of Q2 2026, Paradigm Biocapital Advisors LP holds 480.00K shares of ALNY (ALNYLAM PHARMACEUTICALS INC), valued at $144.49M, representing 2.71% of its reported portfolio and ranking #12.
Has Paradigm Biocapital Advisors LP been buying or selling ALNY?
In the latest 13F filing (Q2 2026), Paradigm Biocapital Advisors LP newly opened its position in ALNY.
Which other funds hold ALNY?
Other major institutional holders of ALNY include T. Rowe Price Investment Management, Inc., Baillie Gifford & Co, Orbis Allan Gray Ltd, among 36 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.